AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18465717 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline infusion)
Number of subjects: 44
Study 16470429 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene (AP) tibial component
Number of subjects: 39
Study 16470429 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed (MB) tibial component
Number of subjects: 39
Study 12208482 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (40 mg/day)
Number of subjects: 58
Study 12208482 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 58
Study 10596735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150-400 mg/day)
Number of subjects: 364
Study 10596735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 364
Study 10596735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 10596735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 364
Study 10596735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 364
Study 10596735 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 364
Study 10596735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR and Sertraline
Number of subjects: 364
Study 8740031 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection (elective)
Number of subjects: 28
Study 8740031 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection (necessary)
Number of subjects: 28
Study 1858760 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cardiovascular monitoring
Number of subjects: 618
Study 1858760 — intervention group
Group type: COMPARATOR
Intervention: Clinical observation (Control)
Number of subjects: 618
Study 6134979 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day omeprazole
Number of subjects: 32
Study 6134979 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day omeprazole
Number of subjects: 32
Study 31402136 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multifaceted intervention consisting of repeated interdisciplinary case conferences (ICCs) involving general practitioners, pharmacists, and nurses, supported by a blended training program and local interdisciplinary meetings.
Number of subjects: 1804
Study 31402136 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1804
Study 30054154 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacking at mid-afternoon (1530h)
Number of subjects: 17
Study 30054154 — intervention group
Group type: COMPARATOR
Intervention: Snacking just after lunch (1230h)
Number of subjects: 17
Study 27184789 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient psychodynamic treatment
Number of subjects: 46
Study 24576541 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy at discharge
Number of subjects: 3512
Study 24576541 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy at discharge
Number of subjects: 3512
Study 22733948 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose TEA group (10 mg/kg intra-operatively)
Number of subjects: 151
Study 22733948 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose TEA group (10 mg/kg pre-operatively and intra-operatively)
Number of subjects: 151
Study 22733948 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 151
Study 21246575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative reflectance/fluorescence spectroscopic technique
Number of subjects: 40
Study 18274163 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nutrition education based on the nutrition triangle concept of UNICEF for 6 months
Number of subjects: 605
Study 18274163 — intervention group
Group type: COMPARATOR
Intervention: Regular BINP services
Number of subjects: 605
Study 16430563 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS beta
Number of subjects: 100
Study 16430563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14530690 — intervention group
Group type: EXPERIMENTAL
Intervention: Degassed aqueous solution made of 40 ml of water and 10 ml of dimethicone emulsion (1 ml/100 mg)
Number of subjects: 100
Study 14530690 — intervention group
Group type: COMPARATOR
Intervention: Conventional degassed water
Number of subjects: 100
Study 10739631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 28
Study 10739631 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 28
Study 10739631 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 28
Study 10739631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem examination of brains
Number of subjects: 28
Study 9124547 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 16
Study 9124547 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 1406817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (10 or 20 mg four times a day)
Number of subjects: 215
Study 1406817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 1406817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 215
Study 6428371 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1.0 to 6.0 mg/day)
Number of subjects: 61
Study 6428371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (500 to 2,000 mg/day)
Number of subjects: 61
Study 6428371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30630891 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEST intervention (consultation to discuss and implement a self-help manual, followed by self-monitoring reminders)
Number of subjects: 551
Study 30630891 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief discussion about lung health)
Number of subjects: 551
Study 29939063 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry male attorney
Number of subjects: 120
Study 29939063 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry female attorney
Number of subjects: 120
Study 29939063 — intervention group
Group type: COMPARATOR
Intervention: Calm female attorney
Number of subjects: 120
Study 29939063 — intervention group
Group type: COMPARATOR
Intervention: Calm male attorney
Number of subjects: 120
Study 25946311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner support
Number of subjects: 10
Study 25946311 — intervention group
Group type: COMPARATOR
Intervention: Physician care alone
Number of subjects: 10
Study 24641941 — intervention group
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ) 60 mg
Number of subjects: 221
Study 24641941 — intervention group
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ) 120 mg
Number of subjects: 221
Study 24641941 — intervention group
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ) 240 mg
Number of subjects: 221
Study 24641941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 221
Study 24641941 — intervention group
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ)
Number of subjects: 221
Study 24641941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg Q4W
Number of subjects: 221
Study 22522225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (400mg and 100mg respectively) administered after a moderate-fat breakfast
Number of subjects: 16
Study 22522225 — intervention group
Group type: EXPERIMENTAL
Intervention: Coprandial administration of formulations
Number of subjects: 16
Study 19693550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper point full length (FP) sampling
Number of subjects: 20
Study 19693550 — intervention group
Group type: COMPARATOR
Intervention: Paper point half length (HP) sampling
Number of subjects: 20
Study 17959861 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 20
Study 17959861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15767505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole
Number of subjects: 3299
Study 15767505 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3299
Study 12389758 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information presented in terms of relative risk reduction
Number of subjects: 100
Study 12389758 — intervention group
Group type: COMPARATOR
Intervention: Risk information presented in terms of absolute risk reduction or number needed to treat
Number of subjects: 100
Study 10613628 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded workload treadmill protocol (G-test; 2 mph; 0% grade, increasing 2% every 2 min)
Number of subjects: 330
Study 10613628 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded workload treadmill protocol (G-test)
Number of subjects: 330
Study 10613628 — intervention group
Group type: COMPARATOR
Intervention: Constant workload treadmill protocol (C-test; 2 mph; 12% grade)
Number of subjects: 330
Study 10613628 — intervention group
Group type: COMPARATOR
Intervention: Constant workload treadmill protocol (C-test)
Number of subjects: 330
Study 7866799 — intervention group
Group type: EXPERIMENTAL
Intervention: TorTourn (ketorolac tromethamine at tourniquet inflation)
Number of subjects: 64
Study 7866799 — intervention group
Group type: EXPERIMENTAL
Intervention: TorEnd (ketorolac tromethamine at the end of surgery)
Number of subjects: 64
Study 7866799 — intervention group
Group type: COMPARATOR
Intervention: TorNone (no ketorolac tromethamine)
Number of subjects: 64
Study 2015162 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg three times daily for 10 days)
Number of subjects: 18
Study 2015162 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg three times daily for 10 days)
Number of subjects: 18
Study 7159883 — intervention group
Group type: EXPERIMENTAL
Intervention: procainamide 1.0 g t.i.d.
Number of subjects: 9
Study 7159883 — intervention group
Group type: EXPERIMENTAL
Intervention: disopyramide 150 mg t.i.d.
Number of subjects: 9
Study 7159883 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31791332 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF-permethrin nets (Olyset Duo)
Number of subjects: 1299
Study 31791332 — intervention group
Group type: COMPARATOR
Intervention: Standard LLINs (Olyset)
Number of subjects: 1299
Study 31791332 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF-permethrin nets
Number of subjects: 1299
Study 31791332 — intervention group
Group type: COMPARATOR
Intervention: PPF-permethrin nets and Standard LLINs
Number of subjects: 1299
Study 29108096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Substance Abuse-Domestic Violence (SADV)
Number of subjects: 63
Study 29108096 — intervention group
Group type: COMPARATOR
Intervention: Drug Counseling (DC)
Number of subjects: 63
Study 27778458 — intervention group
Group type: EXPERIMENTAL
Intervention: 6x/wk hemodialysis
Number of subjects: 245
Study 27778458 — intervention group
Group type: COMPARATOR
Intervention: 3x/wk hemodialysis
Number of subjects: 245
Study 25185754 — intervention group
Group type: EXPERIMENTAL
Intervention: 6:1‐OM3 (4 g/day)
Number of subjects: 110
Study 25185754 — intervention group
Group type: EXPERIMENTAL
Intervention: 6:1‐OM3 (4 g/day) in hypertriglyceridemic subjects
Number of subjects: 110
Study 25185754 — intervention group
Group type: COMPARATOR
Intervention: Placebo: corn oil
Number of subjects: 110
Study 21550779 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance tube phonation for approximately 1 minute
Number of subjects: 20
Study 21550779 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance tube phonation with instruction to keep pitch and loudness consistent
Number of subjects: 20
Study 21550779 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance tube phonation with instruction to maximize ease of phonation
Number of subjects: 20
Study 21550779 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements before tube phonation
Number of subjects: 20
Study 18038188 — intervention group
Group type: COMPARATOR
Intervention: Didactic format (information first)
Number of subjects: 123
Study 18038188 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem format (case first)
Number of subjects: 123
Study 18038188 — intervention group
Group type: COMPARATOR
Intervention: Sensing learners
Number of subjects: 123
Study 18038188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate learners
Number of subjects: 123
Study 18038188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive learners
Number of subjects: 123
Study 18038188 — intervention group
Group type: COMPARATOR
Intervention: Format preference
Number of subjects: 123
Study 18038188 — intervention group
Group type: COMPARATOR
Intervention: Time to complete modules
Number of subjects: 123
Study 17594926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily
Number of subjects: 96
Study 17594926 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 96
Study 16275811 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a 15-session group cognitive therapy prevention program (n = 45)
Number of subjects: 94
Study 16275811 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 49)
Number of subjects: 94
Study 11790656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic test (HT)
Number of subjects: 18
Study 11790656 — intervention group
Group type: COMPARATOR
Intervention: Alternate breath test (ABT)
Number of subjects: 18
Study 9579452 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 gm glucose load
Number of subjects: 60
Study 9579452 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 gm glucose load
Number of subjects: 60
Study 9579452 — intervention group
Group type: COMPARATOR
Intervention: Capillary blood measurement
Number of subjects: 60
Study 9579452 — intervention group
Group type: COMPARATOR
Intervention: Venous plasma measurement
Number of subjects: 60
Study 7537665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastron (Strontium-89)
Number of subjects: 0
Study 7537665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2909288 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg/m2 1 hour before CDDP administration
Number of subjects: 20
Study 2909288 — intervention group
Group type: COMPARATOR
Intervention: No diuretic drug (Control)
Number of subjects: 20
Study 1237234 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated diet for 20 weeks
Number of subjects: 25
Study 1237234 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diet for 20 weeks
Number of subjects: 25
Study 1237234 — intervention group
Group type: COMPARATOR
Intervention: Combined difference between saturated and polyunsaturated diets
Number of subjects: 25
Study 31286728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (at specific acupoints), once every two weeks, six times as a course of treatment, until 12 weeks into pregnancy.
Number of subjects: 60
Study 31286728 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with intramuscular injection of progesterone (40 mg) once every day.
Number of subjects: 60
Study 28111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (250 mg/m2 given twice 1 week apart per cycle)
Number of subjects: 37
Study 28111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with low-dose rituximab
Number of subjects: 37
Study 28111716 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle of low-dose rituximab
Number of subjects: 37
Study 28111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more cycles of low-dose rituximab
Number of subjects: 37
Study 28111716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab
Number of subjects: 37
Study 25988270 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Auricular Point Acupressure (APA) treatment
Number of subjects: 61
Study 25988270 — intervention group
Group type: COMPARATOR
Intervention: Sham Auricular Point Acupressure treatment
Number of subjects: 61
Study 24120678 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+1-dose group (PCV7 at 2, 4, and 11 months)
Number of subjects: 0
Study 24120678 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose group (PCV7 at 2 and 4 months)
Number of subjects: 0
Study 24120678 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at 24 months
Number of subjects: 0
Study 24120678 — intervention group
Group type: COMPARATOR
Intervention: No PCV7 (controls)
Number of subjects: 0
Study 21611896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongjiang granule (TJG) 10 g and mosapride citrate dummy 5 mg three times a day
Number of subjects: 120
Study 21611896 — intervention group
Group type: COMPARATOR
Intervention: Mosapride citrate 5 mg and TJG dummy 10 g three times a day
Number of subjects: 120
Study 18758777 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-free CAOS
Number of subjects: 57
Study 18758777 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based CAOS
Number of subjects: 57
Study 18758777 — intervention group
Group type: COMPARATOR
Intervention: Conventional TK
Number of subjects: 57
Study 16687481 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (12 mg/day for four weeks)
Number of subjects: 14
Study 16687481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15388279 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 35
Study 15388279 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 35
Study 15388279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 16086881 — intervention group
Group type: EXPERIMENTAL
Intervention: China-made tropisetron hydrochloride (5 mg, intravenously)
Number of subjects: 132
Study 16086881 — intervention group
Group type: COMPARATOR
Intervention: Navoban (import tropisetron hydrochloride, intravenously)
Number of subjects: 132
Study 10608948 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutrition supplement (six 235‐mL cans weekly)
Number of subjects: 71
Study 10608948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 71
Study 8527290 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg
Number of subjects: 12
Study 8527290 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 12
Study 8527290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2125513 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron treatment
Number of subjects: 165
Study 2125513 — intervention group
Group type: COMPARATOR
Intervention: Photon treatment
Number of subjects: 165
Study 295576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of L-asparaginase
Number of subjects: 0
Study 295576 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of L-asparaginase
Number of subjects: 0
Study 30789386 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ipilimumab (2010-2015)
Number of subjects: 2793
Study 30789386 — intervention group
Group type: COMPARATOR
Intervention: First-line dacarbazine (2007-2009)
Number of subjects: 2793
Study 28603362 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocervical flexion exercise
Number of subjects: 30
Study 28603362 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipitalis relaxation
Number of subjects: 30
Study 28603362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 26518594 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Model of Performance (UMP) predictions based on psychomotor vigilance task (PVT) lapse data from CSR conditions (3, 5, 7, and 9 hours of sleep/night)
Number of subjects: 14
Study 26518594 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Model of Performance (UMP) predictions for TSD and nap schedules
Number of subjects: 14
Study 24667715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (EndoTAG‐1 22 mg/m(2) + paclitaxel 70 mg/m(2))
Number of subjects: 140
Study 24667715 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoTAG‐1 (2× 44 mg/m(2))
Number of subjects: 140
Study 24667715 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (90 mg/m(2))
Number of subjects: 140
Study 21756154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil)
Number of subjects: 87
Study 21756154 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil
Number of subjects: 87
Study 21756154 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Curcuma aeruginosa
Number of subjects: 87
Study 21756154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 18942100 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement strategy training
Number of subjects: 0
Study 18942100 — intervention group
Group type: COMPARATOR
Intervention: Musculoskeletal exercises
Number of subjects: 0
Study 16837516 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating, structured treatment by social workers
Number of subjects: 194
Study 16837516 — intervention group
Group type: COMPARATOR
Intervention: Routine GP care
Number of subjects: 194
Study 15669588 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening in four rounds every third year
Number of subjects: 9171
Study 15669588 — intervention group
Group type: COMPARATOR
Intervention: Non-screening strategy (Control)
Number of subjects: 9171
Study 12539884 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucarbon (charcoal tablets)
Number of subjects: 284
Study 12539884 — intervention group
Group type: COMPARATOR
Intervention: Carbo ligni (CL)
Number of subjects: 284
Study 9424977 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir, 500 mg orally twice daily for 8 weeks
Number of subjects: 48
Study 9424977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7656833 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose DDP (Cisplatin)
Number of subjects: 72
Study 7656833 — intervention group
Group type: COMPARATOR
Intervention: Fractionated low doses DDP (Cisplatin)
Number of subjects: 72
Study 7656833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 72